United Therapeutics (UTHR) Tops Q3 EPS by 26c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
EPS Growth %: -10.1%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -10.1%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $1.52, $0.26 better than the analyst estimate of $1.26. Revenue for the quarter came in at $242.5 million versus the consensus estimate of $227.63 million.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
